SciSparc shares surge 60.69% premarket after announcing acquisition of MUSE GERD device patents and entering multi-billion-dollar market.

SciSparc surged 60.69% in premarket trading following the announcement of a definitive agreement to acquire a patent portfolio for the MUSE™ single-use endoscopic system from Xylo Technologies. The transaction, set to close on March 8, 2026, involves issuing 19.99% equity to Xylo and grants SciSparc access to a growing $3.03 billion GERD device market by 2030. The MUSE™ system, previously commercialized in China with a $3 million upfront licensing deal, positions SciSparc to replicate this model in North America, Europe, and Latin America. The deal aligns with the company’s strategic pivot into medical device commercialization, enhancing its pipeline alongside its cannabinoid pharmaceutical programs. While separate Nasdaq non-compliance notices raised concerns, the patent acquisition drove immediate investor optimism about market expansion and revenue potential.